At age 62, Australians are entering the period where their superannuation shifts from being a retirement savings tool, to a main source of income.

By this age, you’ve passed the preservation age, which means you can access your superannuation if you’ve quit working. And you’re five years away from receiving the Age Pension (if you’re eligible for it).

But do you know if you have enough in your super to retire?

Or how your superannuation balance compares to other Australians the same age as you?

Here’s a breakdown of what the average superannuation balance is at age 62 in Australia.

Find out how yours compares.

What is the average superannuation balance for men aged 62 in Australia?

There aren’t exact figures, but brackets determined by the Association of Superannuation Funds of Australia (ASFA) provide a good guide.

The data shows that the average Australian male aged 60-64 has around $395,852 in their superannuation.

Is your superannuation in line with the average Aussie the same age?

What is the average superannuation balance for women the same age?

Women the same age have quite a lot less. The average balance for Australian women aged 60-64 is around $313,360. That’s a gap of almost $83,000!

Why? 

Women typically take a career break to have children or care for family, and during this time they receive little to no compulsory employer superannuation. Women are also more likely to work part-time and work in lower-paid industries. The missing contributions in their 30s and 40s also mean they lose several years of compounding, which takes a huge toll on their end balance. 

How does your super balance compare?

Are these average super balances enough to retire on?

If you’re happy to live a basic retirement on a tight budget, possibly. But for a comfortable retirement, no.

In fact, the average Australian is quite far behind.

ASFA estimates that it’ll cost single Australians around $55,923 per year to retire. It’ll cost couples living together closer to $78,566 per year in total.

These figures also assume you’ll start your retirement at age 67. It also assumes that you’ll receive a part Age Pension around this time and that you own your home outright.

In order to fund this type of comfortable retirement, ASFA calculates that single Australians will need around $630,000 in their superannuation at age 67. Meanwhile, couples will need around $730,000 combined at the same age.

So, how much should I have in my super by age 62 to retire comfortably?

Using ASFA’s Super Balance Detective tool, I’ve calculated what you’d need at ages 62 to reach that sum in the next five years.

Assuming you’re aiming for the $630,000 superannuation balance needed for an individual. At age 62, you should have close to $539,000 to be considered ‘on track’.

How does your superannuation balance compare now?

The post The average superannuation balance at age 62 in Australia. How does yours stack up? appeared first on The Motley Fool Australia.

More reading

• How many Brambles shares do I need to buy for $5,000 per year of passive income?
• Australian Strategic Materials confirms scheme effectiveness as takeover completes
• Ventia wins $160 million Victorian ITS contracts, boosting infrastructure services
• Why this ASX 200 stock is a buy after posting record results
• How much are CSL shares worth? 4 brokers have their say

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have staged an impressive recovery over the past three months, aided by a sharp jump this week following the company’s full-year results announcement.

The shares are still more than 25% down over a 12-month period however, begging the question, is there still more recovery to come?

It’s fair to say brokers are split on the question, with those surveyed having a wide range of views on where the shares will go over the next 12 months.

First let’s have a quick look at what CSL announced this week.

Steady results in reset year

The blood products company posted total revenue of US$15.8 billion, down 1%, and underlying net profit of US$3.1 billion, down 2%.

After significant one off costs and write downs were included, the company made a net loss of US$2.6 billion.

Interim Chief Executive Officer Gordon Naylor called FY26 a “reset” year for the company.

On the outlook, the company said it expected underlying net profit to grow by about 5% in FY27.

Wide range of views on CSL Shares

Among the brokers, UBS has the most bullish share price target for CSL at $181, compared to $163.51 late on Wednesday.

The broker said:

CSL has endured a challenging period that required significant restructuring to reduce costs and address the underperforming Vifor division. While more work remains, improving trends in the core plasma business suggest the worst is behind the group and that CSL is on track to return to at least market level growth. The separation of Seqirus is now complete, providing the incoming CEO with additional strategic flexibility.

Morgan Stanley also believes the price will appreciate, with a $172 price target.

They said:

On balance, we see the FY26 result and FY27 guidance as highlighting incremental improvement within CSL Behring, the key driver of group earnings growth over the medium to longer term. Our forecasts imply solid underlying NPATA/NPAT growth, supplemented by an ongoing buyback program.

Meanwhile, Bell Potter has a hold recommendation on CSL, with a price target of $150.

They said:

While the result today suggests the worst (by way of earnings declines) is in the rear-view for CSL, we find it difficult to justify a greater premium than is now being attributed relative to global biopharma peers.

And most bearish on CSL is Macquarie, which has a neutral rating and a price target of just $133.

They said:

Despite signs of stabilisation, we see ongoing uncertainty across core business segments (immunoglobulin, albumin) and medium-term competitive risks.

The post How much are CSL shares worth? 4 brokers have their say appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 shares I’d buy for the next decade
• Here are the top 10 ASX 200 shares today
• CSL shares: 1 number that investors shouldn’t ignore
• CSL shares rebound 79% from multi-year low: Here’s what brokers tip next
• CSL shares just had their best day in 20 years. What did I just miss?

Motley Fool contributor Cameron England has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The long-term buy and hold strategy in ASX shares has been a good one for investors for a long time.

A soft quarter becomes less important, and what matters instead is whether a business will still be comfortably growing its earnings in 2036.

Here are three ASX 200 companies I think comfortably pass that test.

Why I hold ASX shares for a decade

Time is one of the few advantages a retail investor has over a professional fund manager.

Nobody is grading my portfolio every quarter.

That freedom lets me own good businesses through the messy years when the market loses patience.

The three companies below each have a structural growth driver that should still be running long after this reporting season is forgotten.

Wesfarmers: the compounding machine

Wesfarmers Ltd (ASX: WES) may be the closest thing the local market has to a true compounder.

The company’s half-year result delivered revenue of $24.2 billion and net profit after tax of $1.6 billion, up 9.3%.

The interim dividend rose 7.4% to 102 cents per share.

Bunnings did the heavy lifting again, with higher sales across every product category, region and customer segment.

Managing director Rob Scott said:

The result reflects strong operational performance and disciplined execution of the Group’s strategies to create shareholder value.

The real appeal is capital allocation. Wesfarmers has repeatedly recycled cash out of mature businesses and into newer ones, moving from coal into lithium and health.

At today’s prices the stock is not cheap on a price-to-earnings ratio in the low 30s.

But I would rather pay up for a management team that has proven it can redeploy capital sensibly across multiple cycles.

The conglomerate reports its FY26 numbers on 27 August.

Goodman Group: an industrial landlord turned power broker

Goodman Group (ASX: GMG) has become one of the most important data centre developers in the world.

The company’s first-half result delivered $1.2 billion in operating profit. The group’s power bank also expanded from 5GW to 6GW.

By June 2026, more than $14 billion of its roughly $18 billion work in progress is expected to be in data centre projects.

Founder and CEO Greg Goodman said of the strategy:

Power, sites and capital are critical to being able to service demand and provide delivery certainty.

Goodman owns scarce, powered land in exactly the cities where artificial intelligence infrastructure needs to be built.

The units are down roughly 16% over the past year, which strikes me as an opportunity rather than a warning sign.

Goodman reports its FY26 result today.

CSL: a reset year with a long runway

CSL Ltd (ASX: CSL) just posted the ugliest headline number in its ASX history.

FY26 revenue slipped 1% to US$15.8 billion, and impairments of US$7.1 billion pushed the company to a US$2.6 billion statutory loss. Underlying NPATA still landed at US$3.1 billion.

Investors looked past the write-downs to FY27 guidance of roughly 5% underlying profit growth, comfortably ahead of the 2% consensus.

The shares surged 17.9% on results day.

Interim CEO Gordon Naylor framed the year as a clearing of the decks:

CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals.

Plasma collection remains a true moat, because it takes years and enormous amounts of capital to build a competing network of donor centres.

On top of that, a US$1 billion buyback and a flat US$2.92 dividend suggest management believes the worst is now behind it.

The risks of buying these ASX shares today

None of this is free money.

Wesfarmers carries a premium valuation that leaves little room for a consumer downturn.

Goodman is making enormous capital commitments into a data centre market that could eventually oversupply.

Meanwhile, CSL still has to prove Vifor can stabilise after guiding to a roughly 25% revenue decline.

Foolish takeaway

I am not trying to pick the best performers of the next 12 months, but to own businesses that will be much larger in 2036 than they are today.

Wesfarmers, Goodman Group and CSL each have a credible path to that outcome.

For patient investors interested in long-term compounding, that is the bar these ASX shares need to clear.

The post 3 ASX 200 shares I’d buy for the next decade appeared first on The Motley Fool Australia.

More reading

• How much are CSL shares worth? 4 brokers have their say
• Here are the top 10 ASX 200 shares today
• CSL shares: 1 number that investors shouldn’t ignore
• These 3 ASX 200 shares look like classic Warren Buffett investments
• CSL shares rebound 79% from multi-year low: Here’s what brokers tip next

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goodman Group, and Wesfarmers. The Motley Fool Australia has recommended CSL, Goodman Group, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.